

## Immunotech Biopharm Ltd 永泰生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability) (於開曼群島註冊成立的有限公司) (Stock Code 股份代號: 6978)

5 February 2024

Dear registered shareholder(s),

## **Arrangement of Electronic Dissemination of Corporate Communications**

Pursuant to Rule 2.07A and 2.07B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules") under the expansion of paperless listing regime and electronic dissemination of corporate communications that came into effect on 31 December 2023, Immunotech Biopharm Ltd (the "Company") is writing to inform you that the Company has adopted electronic dissemination of corporate communications (the "Corporate Communications"), which mean any documents issued or to be issued by the Company, including but not limited to (a) the directors' report, its annual accounts together with a copy of the auditors' report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) a notice of meeting; (d) a listing document; (e) a circular; and (f) a proxy form.

Please note that both the English and Chinese versions of all future Corporate Communications will be available electronically on the website of the Company at <a href="https://www.eaal.net">www.eaal.net</a> and the HKExnews website at <a href="https://www.hkexnews.hk">www.hkexnews.hk</a> in place of printed copies.

Solicitation of electronic contact details

To ensure timely receipt of the Actionable Corporate Communications (Note), the Company recommends you to provide your email address by scanning your personalized QR code printed on the enclosed reply form on the reverse side of this letter (the "**Reply Form**"). Alternatively, you may sign and return the Reply Form to the Company's Hong Kong branch share registrar (the "**Share Registrar**"), Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong.

If the Company does not receive a functional email address in your reply, until such time that the functional email address is provided to the Share Registrar, the Company will send the Actionable Corporate Communications<sup>(Note)</sup> in printed form in the future.

If you want to receive the Corporate Communications in printed form, please complete and return the Reply Form on the reverse side of this letter to the Share Registrar or send an email to <a href="mailto:immunotech.ecom@computershare.com.hk">immunotech.ecom@computershare.com.hk</a> specifying your name, address and request to receive the Corporate Communications in printed form. Please note that such instruction for receiving the Corporate Communications shall be valid for one year starting from the receipt date of your instruction and will expire thereafter.

Should you have any queries relating to any of the above matters, please contact the Company at (+86) 10 88400295 during business hours from 9:00 a.m. to 6:00 p.m. on Mondays to Fridays, excluding Hong Kong public holidays.

By order of the Board Immunotech Biopharm Ltd Tan Zheng

Chairman and executive Director

Note: Actionable Corporate Communication is any corporate communication that seeks instructions from issuer's securities holders on how they wish to exercise their rights or make an election as the issuer's securities holder.

各位登記股東:

## 以電子方式發佈公司通訊之安排

根據自 2023 年 12 月 31 日起生效的擴大無紙化上市機制及以電子方式發佈公司通訊規定下香港聯合交易所有限公司證券上市規則(「**上市規則**」)第 2.07A 及 2.07B 條,永泰生物製藥有限公司(「**本公司**」)謹此通知 閣下,本公司已採用以電子方式發佈公司通訊(「**公司通訊**」)之安排,該公司通訊是指本公司發佈或將要發佈的任何文件,包括但不限於(a)董事報告、年度帳目以及審計報告副本以及(如適用)財務摘要報告; (b)中期報告及其中期報告摘要(如適用); (c)會議通知; (d)上市文件; (e)通函;和 (f)委任表格。

請注意,所有未來公司通訊的英文版和中文版將在本公司網站 www.eaal.net 和披露易網站 www.hkexnews.hk 上以電子方式提供,以代替印刷本。

徵集電子聯絡資料

為確保及時收到可供採取行動的公司通訊<sup>(欄註)</sup>,本公司建議 閣下透過掃描本函背頁之回條(「**回條**」)上列印的 閣下專屬二維碼來提供 閣下的電郵地址。或者, 閣下也可以簽署回條並交回本公司的香港股份過戶登記分處(「**股份過戶處**」)香港中央證券登記有限公司,地址為香港灣仔皇后大道東 183 號合和中心 17M 樓。

如果本公司沒有收到 閣下回覆的有效電郵地址,直至股份過戶處收到 閣下有效的電郵地址前,本公司未來將以印刷本形式發送可供採取行動的公司通訊  $^{\textit{mer}}$  。

若 閣下希望收取公司通訊之印刷版。請填妥本函背頁之回條並交回股份過戶處。或發送電子郵件至 immunotech.ecom@computershare.com.hk。並註明 閣下的姓名、地址以及收取公司通訊印刷版的要求。 請注意,收取未來公司通訊印刷版之指示由收悉 閣下指示當日起計一年內有效,此後將過期。

如 閣下對上述內容有任何疑問,請於辦公時間星期一至五(香港公眾假期除外)上午9時正至下午6時正致電本公司(+86)1088400295查詢。

承董事會命 **永泰生物製藥有限公司** 主席兼執行董事 **譚錚** 

2024年2月5日



REPLY	FORM	回條
	LOM	

Computershare Hong Kong Investor Services Limited

(the "Share Registrar") 17M Floor, Hopewell Centre,

183 Queen's Road East, Wan Chai, Hong Kong

香港中央證券登記有限公司 (「股份過戶處」) 香港灣仔皇后大道東 183 號 合和中心 17M 樓

(Please <u>choose ONLY ONE</u> of the options below) (請從以下選項中只**選擇其中一項**)

Option 1: Provide your email address for receipt of future Actionable Corporate  $\textbf{Communications}^{(\textit{Note 3})} \ \textbf{of the Company via electronic dissemination by scanning}$ your personalized QR code

Personalized QR Code 專屬二維碼

選項1: 掃描 閣下專屬二維碼提供 閣下之電郵地址,以接收本公司通過電子方式發佈 的未來可供採取行動的公司通訊(附註3)

> You are **NOT required** to return this Reply Form if you choose Option 1. 如選擇了選項 1 · 閣下無須交回本回條。

Option 2: I/we hereby provide my/our email address in writing for receipt of future Actionable Corporate Communications (Note 3) of the following listed					
company (the "Company") via electronic dissemination. <b>選項 2:</b> 本人/吾等現以書面提供本人/吾等之電郵地址,以接收以下上市公司(「本公司」)通過電子方式發佈的未來可供採取行動的公司通訊 <sup>/附註 3)</sup> 。					
Name of securities holder(s) 證券持有人姓名:  Name of the listed company 上市公司名稱:					
Immunotech Biopharm Ltd					
Email address 電郵地址: (Note 3 / 附註 3)					
Option 2. I/we havely request for receipt of Comparets Communications* in printed form (Places mark "/" in the below box if analysis less					

Email address 電郵地址: (Note 3 / 阿缸 3)					
Option 3:   I/we hereby request for receipt of Corporate Communications* in printed form (Please mark "✓" in the below box if applicable)   選項 3: 本人/吾等現要求收取公司通訊*印刷版 (如適用・請在以下方格內劃上「✓」號)					
<b>  選択ろ・  本八日寺が安水収収公司通訊 中側版</b> (知過用・調任以下月刊刊劃上・・」號   receive future Corporate Communications* in printed copy and noted that this instruction is valid only for one year starting from the receipt date of instruction. (Note 5)					
Signature(c). (Note 1)	Contact numbers	Dota			

簽名: (附註 1)

nes 捐註:
Please complete all your details clearly. If your shares are held in joint names, all of the joint shareholders should jointly sign this Reply Form in order to be valid.
請清楚填妥 阁下之所有資料。如屬縣名股東・則本回條須由所有聯名股東聯合簽署・方為有效。
Any Reply Form with no signature or otherwise incorrectly completed will be void.
任何回錄若未有養養或任使地方面填寫不证確,則本回條須由所有聯名股東 will be void.
If the Company does not receive a functional email address in your reply, you will be unable to receive notifications regarding the publication of Actionable Corporate Communications. Actionable Corporate Communication is any corporate communication that seeks instructions from issuer's securities holders on how they wish to exercise their rights or make an election as the issuer's securities holder.
如本公司沒有收到 阁下回覆的有效電影地址 阁下将無法收到有關發佈可供採取行動的公司通訊的通知。可供採取行動的公司通訊指任何涉及要求發行人的證券持有人指示其變如何行使其有關證券持有人的權
制定化即確保証公司海徑可以

聯絡電話號碼:

- 划现下迅速捧树公司短訊。
  If you provide more than one email address by QR code, email, reply form and/or other means, only the latest one email address provided will be registered.

  如 圖下遊過二雄鳴、電影、回線及/或其他方式提供多於一個的電影地址、只有 圖下最後提供的電影地址將會被用於登記。

  If you mark "'" in the box in Option 3, no email address will be registered and only Corporate Communications\* in printed form will be received.

  如 圖下在選項 3 方格內劃上「√」號、將不會有電影地址被登記、只有公司通訊\*的印刷版會被收取。

  For the avoidance of doubt, the Company does not accept any other instructions given on this Reply Form.

  為免存疑。在本回條上的任何額外指示、本公司將不予處理。

- Unless otherwise specified, Corporate Communications refer to any documents issued or to be issued by the Company for the information or action of holders of any of its securities, including but not limited to the annual report, interim report, notice of meeting, circular and proxy form. 除非另有註明,公司通訊乃指本公司已發出或將予發出以供其任何證券的持有人參照或採取行動的任何文件,其中包括但不限於年報、中期報告、會議通告、通函及代表委任表格。

PERSONAL INFORMATION COLLECTION STATEMENT 收集個人資料聲明

- SONAL INFORMATION COLLECTION STATEMENT 收集個人資料聲明
  "Personal Data" in this statement has the same meaning as "personal data" in the Personal Data (Privacy) Ordinance, Chapter 486 of the Laws of Hong Kong ("PDPO").
  本爱帕中所指的"個人資料」與香港法例第 486 章 《個人資料(私隱)條例》(「《私隱條例》」)中「個人資料」的涵義相同。
  Your Personal Data provided in this Reply Form will be used in connection with, including but not limited to, the Company's electronic dissemination of Corporate Communications and to liaise with you on other matters relating to your holdings in the Company. Your supply of Personal Data to the Company is on a case of a failure to provide your sufficient information, the Company may not be able to process your instruction and/or request as stated in this Reply Form.
  國下於本回傳所提供的個人資料用於(內養用學用於) 內國本公司通訊及就 閣下持有的本公司通券有關的其他事宜上與 閣下聯絡。閣下是自顧向本公司提供個人資料。若 閣下未能提供足夠資料。本公司可能無法處理 閣下在本回條上所述的指示及內國東來。
  Your Personal Data may be disclosed or transferred by the Company to its subsidiaries, the Share Registrar, and/or other companies or bodies for any of the stated purposes, or when it is required to do so by law and will be retained for such period as may be necessary for our verification and record purposes.
  本公司可能任何所成期的利用选或任法例规定的情况下。第 閣下的個人資料持應要轉移給本公司的附屬公司、股份過戶處、及/或其他公司或團體。並將在適業期間保留該等個人資料作核實及紀錄用途。
  You have the right to request access to and/or correction of your Personal Data in accordance with the provisions of the PDPO. Any such request for access to and/or correction of your Personal Data in writing, by mail to the Hong Kong Privacy Officer of the Share Registrar at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong or by email at PrivacyOfficer@computershare.com.bt.
- (iii)

Mailing Label 郵寄標籤

Computershare Hong Kong Investor Services Limited 香港中央證券登記有限公司 Freepost No. 簡便回郵號碼: 37 Hong Kong 香港

Please cut the mailing label and stick it on an envelope to return this form to us No postage is necessary if posted in Hong Kong.

日期: